Alerta

BIOMARKER COMPOSITION FOR DIAGNOSIS OF DEGENERATIVE BRAIN DISEASE

Resumen de: US20260328783A1

The present disclosure relates to a biomarker composition for diagnosis of a degenerative brain disease, and more particularly, in an attempt to distinguish between normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients, provides a biomarker composition that distinguishes between the normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients by measuring levels of amyloid beta 40 (Aβ40), amyloid beta 42 (Aβ42), brain-derived neurotrophic factor (BDNF), Tau, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), peptidyl-prolyl isomerase (PIN1), collapsing response mediator protein-2 (CRMP2), phospho-Tau231, and olfactory marker protein (OMP) as biomarkers in the blood to identify correlation thereof.

METHODS, SYSTEMS, AND COMPOSITIONS FOR DIAGNOSING AND TREATING BIOENERGETIC INSUFFICIENCY

Resumen de: US20260325471A1

Disclosed are methods, systems, compositions, and kits for diagnosing, staging, monitoring, and treating conditions associated with bioenergetic insufficiency in a subject or biological system. The disclosure is grounded in the Unified Theory of Bioenergetic Sufficiency (UTBS), which defines cellular health based on maintaining a Metabolic Sufficiency Ratio (M), the ratio of effective energy generation rate (E) to total energy requirement rate (R), above a critical threshold (M=E/R >M_crit). As well as, Metabolic-Epigenetic-Redox Immune Therapy (MERIT), a new therapeutic class of pharmacological, treat-to-target ketone body therapies for diseases characterized by metabolic, redox, epigenetic, or immune dysregulation.

RESPONDER SELECTION AND TREATMENT WITH SIGMA-1 RECEPTOR THERAPY

Resumen de: WO2026221738A1

The present disclosure provides genes and genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy and methods of determining if a subject is responsive or non-responsive to Sigma-1 receptor therapy. The methods can be used to optimize treatment for subjects in need of Sigma-1 receptor therapy. Based on the predicted responsiveness of a subject to the therapy, personalized treatment can be provided to each subject.

NOVEL MARKER FOR DETECTING NEURODEGENERATIVE DISEASES

Resumen de: WO2026222088A1

The present disclosure describes a method of isolating neuronal-derived extracellular vesicles (NEVs) and obtaining an enriched population of NEVs. The enriched population of NEVs can be used for detecting neurodegenerative diseases. As described herein, ICAM-5 is a specific neuronal marker present on NEVs and offers a highly specific method for NEVs enrichment. Various implementations of the present disclosure provide enhanced sensitivity and accuracy of biomarker detection for neurodegenerative diseases. The high CNS specificity associated with ICAM-5, compared to other reported markers, can significantly improve diagnostic modalities by providing more reliable information that accurately reflects the molecular changes in the brain, leading to earlier and more precise diagnoses.

NOVEL MULTIPLEX NULISA-BASED ASSAY TO DETECT MULTIPLE FORMS OF PHOSPHORYLATED BRAIN-DERIVED TAU AND TOTAL TAU IN BLOOD

Resumen de: WO2026222207A1

Disclosed herein are highly sensitive NULISA immunoassays that utilize a capture/release mechanism to reduce non-specific binding and achieve detection with attomolar-level sensitivity to detect multiple forms of phosphorylated brain-derived Tau and total Tau in blood. Kits that can be used for carrying out these highly sensitive immunoassays are also disclosed herein.

METHOD FOR ISOLATING ANTIGEN MOLECULE

Resumen de: US20260328775A1

0000 Provided is a method of efficiently isolating and detecting an antigen molecule from an antigen-antibody complex in a biological sample. Provided is a method of isolating an antigen molecule from a liquid sample comprising an antigen-antibody complex, the method including: a binding step of binding the antibody molecule in the antigen-antibody complex to an antibody-binding protein by applying the liquid sample to a column on which the antigen-binding protein is immobilized; and an elution step of eluting an elution liquid comprising the antigen molecule by applying a buffer liquid to the column to dissociate the antigen molecule in the antigen-antibody complex from the antibody molecule, wherein the buffer liquid is applied to the column while the pH of the buffer liquid decreases in a continuous or stepwise manner in the elution step.

バイオマーカー及び生体分子をタグ付けするのに有用な芳香族アルキン化合物

Resumen de: WO2025062119A2

The invention relates to a compound of formula I, wherein: A, B, R1, R2, L1, m and n are as defined in the specification, or a salt or solvate thereof, which compounds are useful for forming Raman-tagged bioconjugates with a biomarker and/or biomolecule and are detectable with Raman spectroscopy

METHODS FOR PREDICTING RISK FOR INFLAMMATION

Resumen de: EP4826385A1

The present invention relates to method of determining risk of an inflammatory condition, and/or risk of progression of an inflammatory condition, as well as to compounds for use in these methods.

方法及びマイクロバイオーム組成物の使用

Resumen de: US2022082552A1

0001 Methods and uses of compositions (e.g. comprising one or more microbial strains) are disclosed.

一种磁性免疫富集微流控芯片及其在磷酸化Tau蛋白检测中的应用

Resumen de: CN122937868A

本发明公开一种磁性免疫富集微流控芯片及其在电致发光下对p‑Tau217的检测方法，属于微流控生物检测领域。芯片包括可拆合的主体板和底板，主体板设有样品、检测探针及洗涤液/共反应剂进样口，三路流道汇合后经蛇形通道与富集混合反应腔连通。反应腔下方设可移动磁体，用于截留、原位洗涤和释放携带夹心免疫复合物的SiO2@Fe3O4磁珠。富集后的磁珠复合物经出口导入三电极电化学发光检测池进行信号采集。本发明利用蛇形流道、回流抑制结构、圆角过渡及可移动磁场，减少磁珠沉积和非特异性背景，适用于离体血清或血浆样本中p‑Tau217的体外定量检测。

包括基于微免疫珠的电磁操作系统的微流控装置和其使用方法

Resumen de: US20260316074A1

0000 Microfluidic devices and methods for automated analyte detection are provided. The microfluidic devices contain a biochip and an electromagnetic (EM) chip with a programmable navigation matrix. The biochip includes a sample loading chamber, one or more wash chambers, a binding chamber, a detection chamber, and optionally a stop buffer chamber, all of which may be in fluid communication with each other. Immunomagnetic exosome beads can be pre-loaded or added separately to capture target analytes. The EM chip contains electromagnetic coils, switching circuits, magnetic motors, and a microcontroller that activates the coils to manipulate the beads. The coils are aligned with the chambers in the biochip. Optionally, the device includes an optical module for signal detection and an operation module for signal processing.

靶向IL-6R和α4β7的双特异性抗体及其应用

Resumen de: CN122953248A

本公开属于生物医药领域，具体涉及靶向IL‑6R和α4β7的双特异性抗体及其应用。本公开的靶向IL‑6R和α4β7的双特异性抗体对IL‑6R和/或α4β7具有较好的亲和力和/或生物学活性，可用于检测IL‑6R和/或α4β7、诊断或防治与IL‑6R和/或α4β7相关的疾病或病症。

間質性肺疾患の処置のためのバイオマーカー

Resumen de: WO2022182949A2

The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2/3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.

脳内リン恒常性促進剤に基づく治療法

Resumen de: WO2025016362A1

The present invention relates to the field of biomedicine, in particular, to the use of an intracerebral phosphate homeostasis promoter in cerebral calcification diseases. The intracerebral phosphate homeostasis promoter comprises an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene or an agent targeting astrocytes. In addition, further provided in the present invention are an agent capable of regulating alternative splicing in an intron of the SLC20A2 gene, and the use thereof. Further provided in the present invention are a cerebral calcification model based on alternative splicing in an intron of the human SLC20A2 gene, and a preparation method therefor and the use thereof.

用于识别轻度认知障碍的生物标志物及其应用

Resumen de: CN122922398A

本发明涉及生物医药领域，具体涉及用于识别轻度认知障碍的生物标志物及其应用。该生物标志物，包括S‑腺苷同型半胱氨酸、黄体酮、溶血磷脂LPE 22:1、丙酸、β‑m‑羟基苯基‑羟基丙酸、雌二醇、17α‑羟孕酮、鞘磷脂SM 44:4、L‑哌啶酸、乙醇酸、雄烯二酮、L‑赖氨酸等中的至少一种。通过利用本发明实施例的生物标志物，实现了高灵敏度、高准确度的MCI检测方法，不仅在性能上显著提升了现有技术的检测能力，还大幅降低了检测的成本和操作的复杂性，对认知功能障碍的早期诊断具有重要的临床应用价值。

筛选野生型α-突触核蛋白聚集抑制剂和纤维解聚剂的方法和试剂盒及其应用

Resumen de: CN122922424A

0001 本发明属于医药技术领域，公开了筛选野生型α‑突触核蛋白聚集抑制剂和纤维解聚剂的方法和试剂盒及其应用。本发明以振荡温育法诱导重组人源野生型α‑突触核蛋白单体聚集，通过在聚集起始/形成纤维后与待测物质共同孵育，通过硫黄素‑T(ThT)荧光反应检测溶液中野生型α‑突触核蛋白聚集形成的β‑折叠的含量变化，由荧光值大小反映溶液中野生型α‑突触核蛋白的聚集程度，达到筛选抑制野生型α‑突触核蛋白聚集和促进野生型α‑突触核蛋白纤维解聚活性物质的目的，有益于发现靶向野生型α‑突触核蛋白聚集的先导物。

银杏酮酯中的碟豆素在改善神经炎症类认知障碍上的应用

Resumen de: CN122911999A

本发明涉及神经炎症下的认知障碍疾病技术领域，具体地说是银杏酮酯中的碟豆素在改善神经炎症类认知障碍上的应用。采用如下步骤：S1，通过分子对接筛选银杏酮酯入脑成分中可能作用于NKAα1的活性单体，并通过CETSA验证其与NKAα1的直接结合能力；S2，在LPS+ATP诱导的小胶质细胞炎症模型中，系统评估该单体对NKAα1内吞、NKAα1‑P2X7R相互作用、P2X7R介导电流及K⁺外流、以及NLRP3炎症小体激活的调控作用；S3，通过整体动物水平实验进一步探讨碟豆素改善PScDKO小鼠认知障碍的以及对NKAα1‑P2X7‑NLRP3信号轴的调控作用。同现有技术相比，分子对接结果表明银杏酮酯入脑成分碟豆素和水仙苷与NKAα1具有较好的结合能力；碟豆素和水仙苷在实验浓度范围内对BV2细胞活力无明显影响，并能抑制LPS+ATP诱导的炎症因子产生。

METHODS OF DIAGNOSING AND TREATING MOOD AND PSYCHOTIC DISORDERS USING LYMPHOCYTE BIOMARKERS

Resumen de: AU2025231883A1

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection/analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

METHODS AND COMPOSITIONS FOR MEASURING AND MANAGING OXIDATIVE STRESS LEVELS

Resumen de: AU2025231935A1

Provided herein are methods for providing personalized antioxidant supplement blend for an individual subject based on the levels of antioxidant biomarkers, prooxidant biomarkers, and genetic statuses. The antioxidant supplement blend includes suggestions for one or more of diet, supplements, and/or life style changes for the individual.

Method of nociceptor differentiation of human embryonic stem cells and uses thereof

Resumen de: AU2026237984A1

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling. ep e p

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME

Resumen de: US20260317373A1

The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

SINGLE CELL SUPER-RESOLUTION PROTEOMICS

Resumen de: US20260318900A1

0000 Disclosed are methods for full morphological labeling of individual neurons from any species or cell type for subsequent cell-delineated protein analysis. These methods, which combines patch-clamp electrophysiology with epitope-preserving magnified analysis of proteome (eMAP), additionally allow for correlation of physiological properties with subcellular protein expression.

METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY

Resumen de: US20260315577A1

0000 The present disclosure relates to compositions and methods useful for assessing the hemostatic efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor. The method can include administering to the patient a fXa derivative that has reduced catalytic activity as compared to the wild-type fXa protein, is capable of binding to the factor Xa inhibitor and cannot assemble into a prothrombinase complex; obtaining a blood sample from the patient following the administration; and measuring an anti-fXa activity in the sample, wherein the anti-fXa activity reflects the hemostatic efficacy in the patient. Once the assessment is made, suitable medical interventions can be implemented.

METHOD TO DETERMINE THE EFFICACY OF A NEURODEGENERATIVE DISEASE TREATMENT

Resumen de: US20260318926A1

The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.

Systems, Compositions, and Methods to Control the Integrated Stress Response

Nº publicación: US20260317734A1 15/10/2026

Solicitante:

THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University of California

Resumen de: US20260317734A1

0000 Many embodiments are directed to systems, compositions, and methods to control the ISR. Numerous embodiments utilize optogenetic control to control the ISR. Optogenetic control can be provided by an engineered ISR kinase that can dynamically stimulate the ISR pathway. Using optogenetic control, many embodiments enable the selective activation of a single kinase of the ISR pathway without inducing real molecular damage, greatly reducing the combinatorial complexity of the signals that are turned on by real stressors. By changing the intensity of light stimulation, various embodiments can tune the fraction of optogenetic proteins in the activated state, thereby precisely altering the perceived intensity. Additionally, precisely defined input dynamics can be delivered by toggling lights between on and off positions. Many embodiments are scalable and/or capable of high-throughput delivery, allowing for precise dissections of the ISR pathway.